SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCJuly 14, 2026

Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date

A group of thoracic oncologists from Europe and Israel has published the largest real-world account to date of trastuzumab deruxtecan in HER2-mutant lung cancer, a setting where practice has so far rested largely on a single-arm trial. Writing in the Journal of Thoracic Oncology, Oliver Illini and colleagues report outcomes for 168 patients treated outside clinical studies, and find that the activity seen in the trial, including inside the brain, broadly held up in routine care. Several of the authors are Lung Summit faculty, among them the senior author, Maximilian Hochmair.
Share

In brief

  • A multinational team reports the largest real-world cohort so far of patients with advanced HER2-mutant non-small cell lung cancer treated with trastuzumab deruxtecan (T-DXd) outside clinical trials: 168 patients across 68 centres in Europe and Israel.
  • The objective response rate was 54.8% and disease control rate 88.7%, with a median progression-free survival of 7.2 months and a median overall survival of 18.3 months. Treatment-naive patients responded more often (72.2%).
  • Among the 27 patients with measurable brain metastases, the intracranial response rate was 74.1%, a group largely excluded from the earlier registration trials.
  • Interstitial lung disease or pneumonitis occurred in 14% of patients, including four fatal cases, and the authors describe it as the main safety concern.

Read the full paper in the Journal of Thoracic Oncology →

Background

HER2 mutations are found in a small share of non-small cell lung cancers and define a distinct subset that is now treatable with drugs aimed at the alteration. Trastuzumab deruxtecan, an antibody-drug conjugate that links a HER2-directed antibody to a chemotherapy payload, showed strong activity in the DESTINY-Lung studies and entered practice on that basis. The authors note that data from everyday use, where patients are older, sicker and more varied than those enrolled in trials, had been limited.

To close that gap, the investigators assembled a retrospective cohort under the TRACER/HERTras collaboration, pooling records from patients treated between August 2021 and January 2025. Their aim was to test whether the efficacy and safety recorded in the registration programme carried over to unselected patients, and to look specifically at two groups that trials tend to leave out: those treated in the first line and those with active brain metastases.

Study at a glance

  • Cohort: TRACER/HERTras real-world cohort (retrospective, multinational)
  • Population: 168 patients with advanced HER2-mutant NSCLC treated outside trials; 68 centres across Europe and Israel; August 2021 to January 2025
  • Treatment: trastuzumab deruxtecan (T-DXd), across treatment lines
  • Primary endpoint: objective response rate, 54.8% (95% CI 46.9 to 62.4)
  • Survival: median PFS 7.2 months; median OS 18.3 months
  • First line (n=18): response rate 72.2%; median OS 22.1 months
  • Brain metastases (n=27): intracranial response rate 74.1%, including 25.9% complete responses
  • Safety: grade 3 or higher treatment-related events in 32%; interstitial lung disease or pneumonitis in 14% (four fatal)

What the cohort showed

Across the 168 patients, whose median age was 62 years and of whom 56% had never smoked, the objective response rate was 54.8% and the disease control rate 88.7%. Median progression-free survival was 7.2 months and median overall survival 18.3 months. The authors report that these figures sit close to those recorded in the DESTINY-Lung02 trial, which they take as evidence that the drug performs in routine practice much as it did under trial conditions.

The 18 patients who received trastuzumab deruxtecan as their first treatment did notably better, with a response rate of 72.2% and a median overall survival of 22.1 months. The authors are careful about the number, since first-line use was uncommon in the cohort and the group is small, but they note that it adds to the case for testing the drug earlier in the disease course, which is the question several ongoing trials are designed to answer.

Activity against brain metastases

Brain metastases are common in HER2-mutant lung cancer and were an explicit focus of the analysis. Among the 27 patients with measurable intracranial disease, the response rate inside the brain was 74.1%, and about a quarter of that group had a complete intracranial response. Because patients with active brain metastases were largely kept out of the registration trials, the authors present this as one of the cohort’s more useful contributions, offering a read on a question clinicians face regularly but had little trial data to answer.

“In the largest real-world cohort reported to date, T-DXd demonstrated robust systemic and intracranial activity in HER2-mutant NSCLC, including treatment-naive patients and those with active brain metastases who were largely excluded from prior studies.”Illini et al., Journal of Thoracic Oncology (2026)

Safety

Treatment-related adverse events of grade 3 or higher occurred in 32% of patients, which the authors describe as consistent with previous reports. The signal they single out is interstitial lung disease or pneumonitis, a known risk with this drug, which affected 14% of the cohort and was fatal in four cases. They found no consistent predictor of who would develop it, and frame it as the principal safety concern to weigh when using the drug, particularly given that the real-world population is broader than the trial population.

What the authors conclude

The investigators conclude that trastuzumab deruxtecan showed robust systemic and intracranial activity in this unselected population, and that its performance supports building HER2-directed treatment into the way HER2-mutant lung cancer is managed. They temper that with the retrospective design, the modest numbers in the first-line and brain-metastasis subgroups, and the continuing need to watch for lung toxicity.

Sources

  1. Journal of Thoracic Oncology. Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date (2026-02-24). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Maximilian Hochmair, Giannis Mountzios, Alfredo Addeo and Martin Reck.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

N. Reguart
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
Girard ADCs
Oct 05 2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu